Troscriptions

Supplement

Pharmaceutical-grade buccal troches, developed by physicians that leverage novel ingredients such as methylene blue, cordycepin, and agarin to enhance cellular function, stress, sleep, and immune resilience.

Services
  • Troscriptions
Location Dover, DE
About

Troscriptions

Troscriptions is a physician-formulated health optimization company delivering pharmaceutical-grade formulations via buccal troches for rapid, reliable absorption and high patient adherence. Developed by practicing clinicians, our products support mitochondrial function, cognitive performance, stress resilience, sleep, and inflammatory balance—tools practitioners can use now while guiding long-term optimization. No fluff. No guesswork. Just precision formulations designed to help you move patients toward measurable, repeatable physiologic balance — one troche at a time.

What We Offer

Services

Physician-formulated buccal troches for energy, focus, sleep, stress, and immune system optimization using novel compounds like methylene blue, cordycepin, agarin, and more.

Unlock exclusive discounts and offers from Troscriptions and other trusted partners with an SSRP Pro Membership.
What People Say

Testimonials

“Troscriptions has been integral in helping my patients recover from a variety of conditions that have stolen their energy and cognitive capacity. I’m thrilled by how many patients successfully transition off various medications with their help.”

Dr. Stephanie Rimka, DC
Dr. Stephanie Rimka, DC Dr. Stephanie Rimka

“Troscriptions products have been game changing in my clinical practice. Having tried numerous products, Troscriptions is the only brand that consistently receives glowing feedback from patients and truly moves the needle on their health challenges, something in only a few days.”

Dr. Ashley Beckman
Dr. Ashley Beckman Dr. Ashley
Network with our partners

Upcoming Events

View Upcoming Events
EVENT
Grand Rounds
December 4 - 5, 2026

Grand Rounds

Coming Soon
RESOURCES

Join us in breaking down the latest research live.

VIEW ALL
PODCAST
Redox Revolution
Sep 15, 2026
Ep.77 – Enhancing Orthopedic Outcomes and Improving Healing in Patients with Dr. Rahman
Ep.77 – Enhancing Orthopedic Outcomes and Improving Healing in Patients with Dr. Rahman

Dr. Seeds sits down with Omar Rahman, M.D. to talk about how peptide therapy can enhance orthopedic outcomes and speed up healing in patients.

Peptides & Protocols · Performance & Recovery
SSRP Institute Sep 14, 2026
In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD
HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]
READ NEWS
EVENT
Certification
September 10 - 11, 2027
Peptide Therapy Certification 2027
Four Seasons Resort Orlando at Walt Disney World, FL
COMING SOON
Certification
Peptide Therapy Certification 2027
COMING SOON
EVENT
World Congress
June 17 - 19, 2027
Peptide World Congress 2027
Arizona Biltmore, Phoenix, AZ
COMING SOON
World Congress
Peptide World Congress 2027
COMING SOON
EVENT
Mastermind
February 15 - 19, 2027
Fellowship Mastermind Summit 2027
Gansevoort Meatpacking NYC, New York, NY
COMING SOON
Mastermind
Fellowship Mastermind Summit 2027
COMING SOON
EVENT
Grand Rounds
December 4 - 5, 2026
Grand Rounds
Four Seasons Resort and Residences Vail
COMING SOON
Grand Rounds
Grand Rounds
COMING SOON
VIDEO
Cellular Medicine Mondays
Sep 14, 2026
Ep. 105 - Dr. Seeds’ Office Hours
Preview Only
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
HEADLINE SCIENCE [August 27, 2026] – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
SSRP Institute Aug 21, 2026
Alpha-Gal Syndrome: An Update on Incidence Rate by the CDC
HEADLINE SCIENCE [August 21, 2026] – JAMA recently published a report about the incidence rate of alpha-gal syndrome, which is a serious allergic reaction to a sugar molecule called alpha-gal, which is found in most mammals. It is typically transmitted through a bite from a Lone Star tick or other tick species that injects the […]
READ NEWS
IntellxxDNA Aug 12, 2026
SSRP Institute Welcomes IntellxxDNA as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [August 12, 2026] — The SSRP Institute welcomes IntellxxDNA to its Trusted Partner Network following a nomination and internal vetting process, aligning with SSRP’s mission to advance science-first, education-driven clinical collaboration. IntellxxDNA provides clinicians with a structured genomic decision support platform that translates complex genetic data into clinically actionable insights. Using […]
READ NEWS
ARTICLE
William Seeds, MD
Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
William Seeds, MD Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
Mitochondrial dysfunction is one of the most firmly established hallmarks of aging, but the field has spent far more energy describing genetic causes of mitochondrial failure—mtDNA mutation, defective OXPHOS, impaired unfolded protein response—than the “natural” drivers that erode mitochondria during ordinary aging. As I discussed in my recent June Journal Club (as well as a […]
READ ARTICLE